Trial Profile
Luseogliflozin (TS-071), a Selective SGLT2 Inhibitor, Improves Glycemic Control and Lowers Body Weight in Japanese Patients with Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2021
Price :
$35
*
At a glance
- Drugs Luseogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Taisho Pharmaceutical
- 12 Sep 2021 Results of pooled analysis of three studies JapicCTI090908, JapicCTI101191 and JapicCTI11166116 published in the Journal of Clinical Pharmacology
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 28 Jun 2012 New trial record